Señales en vivo de PRTC.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 may 2024 @ 11:37):

Stats
Volumen de hoy	115 557
Volumen promedio	528 633
Capitalización de mercado	578.25M
EPS	£0 ( 2024-04-25 )
Próxima fecha de ganancias	( £0 ) 2024-06-12
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-11.26
ATR14	£0.634 (0.29%)

Volumen Correlación

Largo: 0.27 (neutral)

Corto: 0.20 (neutral)

Signal:(56.904) Neutral

PureTech Health PLC Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PureTech Health PLC Correlación - Moneda/Commodity

-0.67
( moderate negative )

-0.59
( weak negative )

-0.31
( neutral )

-0.11
( neutral )

0.23
( neutral )

PureTech Health PLC Finanzas

Annual	2023
Ingresos:	£750 000
Beneficio Bruto:	£750 000 (100.00 %)
EPS:	£-0.240

FY	2023
Ingresos:	£750 000
Beneficio Bruto:	£750 000 (100.00 %)
EPS:	£-0.240

FY	2022
Ingresos:	£2.09M
Beneficio Bruto:	£2.09M (100.00 %)
EPS:	£-0.130

FY	2021
Ingresos:	£17.39M
Beneficio Bruto:	£0.00 (0.00 %)
EPS:	£-0.214

Financial Reports:

No articles found.

PureTech Health PLC

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.